SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on April 27, 2001 and is headquartered in Norwest, Australia.

Incannex Healthcare Inc

Incannex Healthcare Limited - ADR

Incannex Healthcare (IXHL) is experiencing a surge in momentum, largely driven by its imminent NASDAQ compliance and intense speculation surrounding potential positive End-of-Phase 2 results for its Fast Track-designated sleep apnea drug. The community is actively discussing the stock's severely undervalued market cap relative to its cash and pipeline, anticipating a significant re-rating and potential short squeeze from the newly tightened float.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending after reporting robust quarterly earnings, including beats on revenue and EPS, achieving full-year GAAP profitability, and announcing a significant new share buyback, which sparked a perplexing after-hours dip. The community is actively debating whether this decline is market manipulation or an exceptional buying opportunity, particularly given the company's strategic pivot into Agentic AI and discussions around potential government contracts.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending following the successful Alpha Flight 7 mission, generating significant community excitement and bullish sentiment. This launch success, combined with its inclusion in the lucrative "Golden Dome" defense initiative and broader sector enthusiasm, is fueling discussions about the company's growth trajectory.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending on strong anticipation of a major hyperscaler tenant announcement for its expanding AI data center campus, amplified by recent strategic land acquisitions for significant power generation capacity. The community is buzzing about its potential in the critical energy-digital infrastructure sector, despite some impatience surrounding the timing of the official news.

Lightwave Logic, Inc. is a development stage company which engages in the commercialization of electro-optic photonic devices. The firm offers the P2ICTM technology platform which uses in-house proprietary organic polymers. Its products include electro-optical modulation devices and proprietary polymer photonic integrated circuits. The company was founded on June 24, 1997 and is headquartered in Englewood, CO.

Lightwave Logic Inc

Lightwave Logic is surging after announcing a development agreement with Tower Semiconductor to integrate its electro-optic polymer modulators into Tower's silicon photonics platform, with the community actively discussing the potential Nvidia connection and its implications for next-generation AI and data center optical interconnects.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is a central topic of discussion as small-cap stocks face heightened pressure from escalating geopolitical tensions and rising oil prices. The community is actively debating its notable underperformance and greater sensitivity compared to broader market indices during this period of uncertainty.

Lennar Corp. engages in the provision of real estate related financial and investment management services. It operates through the following segments: Homebuilding, Financial Services, Multifamily, and Lennar Other. The Homebuilding segment refers to the construction and sale of single-family attached and detached homes and the purchase, development, and sale of residential land directly and through entities. The Financial Services segment focuses on mortgage financing, title, and closing services for buyers. The Multifamily segment is involved in the development, construction, and property management of multifamily rental properties. The Lennar Other segment includes funds, asset management platform, and strategic investments in technology companies. The company was founded in 1954 and is headquartered in Miami, FL.

Lennar Corp. - Ordinary Shares - Class A

Lennar Corp.

Lennar (LEN) is experiencing significant discussion in the homebuilding sector following its recent mixed earnings, which showed squeezed margins despite an increase in new orders. Community sentiment is divided, with many bulls anticipating a market rebound driven by expected Fed rate cuts and potential government initiatives to boost affordability, while bears focus on persistent high interest rates and broader housing market weakness.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Investors are actively debating the high distribution yield of Icahn Enterprises and potential for a short squeeze, fueled by optimism surrounding its CVI Energy holdings benefiting from current energy market dynamics and its indirect exposure to a possible SpaceX IPO. This comes as the company continues strategic asset realignments and Carl Icahn makes new investments, keeping the community focused on dividend sustainability and future growth.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BCRX is trending due to its upcoming Q4/FY2025 earnings report and highly anticipated Navenibart data from the ALPHA-SOLAR trial, building on the recent Astria Therapeutics acquisition and ORLADEYO's pediatric approval, with the community actively debating significant short interest and the drug's potential for best-in-class dosing.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is trending as escalating attacks disrupt shipping in the Strait of Hormuz, driving crude oil prices higher despite a historic 400 million barrel global reserve release, fueling a sharp debate among investors on whether prices will continue to surge or eventually crash.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - HC Wainwright decreased their Q1 2026 earnings per share estimates for Keros Therapeutics in a report released on Thursday, March 5th. HC...

Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Keros Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?

KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.

What is HC Wainwright's Estimate for KROS FY2030 Earnings?

Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for Keros Therapeutics in a research report issued to clients and...

Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?

Reblozyl tops $2.3B in annualized sales, emerging as a key drug for Bristol Myers as demand rises in MDS-related anemia and new study data support expansion.

Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00

Wells Fargo & Company cut their price target on Keros Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Thursday...

Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of -75.51% and -94.08%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results

Keros Therapeutics (NASDAQ:KROS - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus...

Keros Therapeutics Touts Rinvat ercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference

Keros Therapeutics (NASDAQ:KROS) CEO Jasbir Seehra outlined the company's development priorities and partnership plans during a presentation at Oppenheimer's 36th Annual Healthcare Life Sciences...

Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position

Western Standard LLC increased its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 42.7% during the third quarter, according to the company in its most recent disclosure...

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$1.03	--	--	N/A
Q4 '25	-$0.70	-$0.86	-23.36%	MISSED
Q3 '25	-$1.05	-$0.18	82.82%	BEAT
Q2 '25	-$1.11	-$0.76	31.52%	BEAT
Q1 '25	-$1.15	$3.62	414.96%	BEAT

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest KROS News

KROSKeros Therapeutics Inc